论文部分内容阅读
目的探讨液基细胞学检测方法(TCT)及高危型人乳头瘤病毒(HPV)DNA检测在宫颈癌前病变(CIN)或宫颈癌中临床应用价值。方法对我院妇科350例(其中30岁以下患者103例,30岁以上患者247例)宫颈疾病患者行TCT宫颈细胞学检查,同时行高危型HPV-DNA检查,阳性病例给予病理组织学确诊。结果发现TCT+HPV双阳性及TCT或HPV单纯阳性病例90例,经行宫颈病理组织学诊断,确诊宫颈癌前病变73例,占81.11%(73/90)。其中高危HPV+TCT检测双阳性68例,占宫颈癌前病变确诊病例93.15%(68/73)。在30岁以下组和30岁以上组双阳性率分别为15.53%和21.05%,病理确诊宫颈癌前病变病例30岁以下组和30岁以上组分别为17.47%和22.26%。结论 TCT联合高危HPV检测在临床初筛宫颈癌前病变或宫颈癌中漏诊率低,操作简单,无创伤,对高危人群,特别是30岁以上的妇女有积极的防癌作用,适用于临床上进行宫颈癌前病变广泛筛查。
Objective To investigate the clinical value of liquid-based cytology (TCT) and high-risk human papillomavirus (HPV) DNA testing in cervical precancerous lesions (CIN) or cervical cancer. Methods The gynecological department of our hospital 350 cases (including 103 patients under 30 years of age, 247 patients over 30 years old) cervical disease TCT cervical cytology, while high-risk HPV-DNA examination, positive cases given histopathological diagnosis. The results showed that TCT + HPV double positive and 90 TCT or HPV positive cases were diagnosed by cervical histopathology, 73 cases were diagnosed as cervical precancerous lesions (81.11%, 73/90). Among them, 68 were double-positive HPV-positive and TCT-positive, accounting for 93.15% (68/73) of cases diagnosed as cervical precancerous lesions. The positive rates were 15.53% and 21.05% respectively in the group of 30 years old and above 30 years old, and the cases of cervical precancerous lesions in the group of 30 years old and younger than 30 years old were 17.47% and 22.26% respectively. Conclusion TCT combined with high-risk HPV testing in clinical preclinical screening of cervical precancerous lesions or cervical cancer in the low rate of missed diagnosis, simple operation, non-invasive, high-risk groups, especially women over the age of 30 have a positive anti-cancer effect, suitable for clinical Cervical precancerous lesions for extensive screening.